Table 1.
Study population break down
| All patients | |||
|---|---|---|---|
| WL-TURBT | PDD-TURBT | p value | |
| Screened | 438 | 370 | |
| Median age (25, 75) | 71.9 (64.4–80.1) | 72.1 (62.2–79.8) | 0.30 |
| NMIBC at first TURBT | 296 (66.8) | 258 (69.7) | 0.51 |
| Good quality TURBT for NMIBC (included) | 153/296 (51.7) | 192/258 (74.4) | <0.001 |
| Risk groups | |||
| Low (G1/G2 Ta, single and <3 cm) | 65 (43.0) | 57 (29.7) | 0.01 |
| Intermediate (G1/G2, Ta/T1, ≥3 cm or multiple and <3 cm) | 45 (29.8) | 71 (37.0) | 0.14 |
| High (high risk: G3, Ta/T1 including cis) | 41 (27.2) | 64 (33.3) | 0.19 |
| CIS at first resection | 6/153 (3.9) | 10/192 (5.2) | 0.57 |
| T1 | 27/153 (17.6) | 45/192 (23.4) | 0.19 |
| Unifocal | 113/153 (73.9) | 98/192 (51.0) | <0.001 |
| >3 tumours | 12/157 (7.8) | 59/192 (30.7) | <0.001 |
| Re-TURBT in high-risk patients | 34/41 (82.9) | 55/64 (85.9) | 0.95 |
| Primary BCG in high-risk patientsa | 11/41 (26.8) | 13/64 (20.3) | 0.45 |
| Follow-up | |||
| Median follow-up (25, 75) | 53.0 (19.9–65.5) | 36.6 (22.3–43.2) | <0.001 |
| Completed 3-year follow-up | 105/153 (68.6) | 127/192 (66.1) | 0.65 |
a Local guidelines for BCG therapy were followed and did not change through the study, these stipulated that BCG would only be given immediately after first TURBT if there was CIS or multifocal G3, otherwise BCG could be deferred until detection of recurrent or residual high-grade disease